{"id":"NCT01412060","sponsor":"Forest Laboratories","briefTitle":"A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Cariprazine (RGH-188) in the Prevention of Relapse in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09-27","primaryCompletion":"2014-09-03","completion":"2014-09-03","firstPosted":"2011-08-08","resultsPosted":"2018-07-06","lastUpdate":"2018-07-06"},"enrollment":765,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Cariprazine","otherNames":["RGH-188"]}],"arms":[{"label":"Cariprazine - Open-label Phase","type":"EXPERIMENTAL"},{"label":"Placebo - Double-blind Treatment Phase","type":"EXPERIMENTAL"},{"label":"Cariprazine - Double-blind Treatment Phase","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.","primaryOutcome":{"measure":"Time From Baseline to the First Symptom Relapse During the Double-blind Phase","timeFrame":"Up to 34 Weeks and Bi-Weekly thereafter until Week 92","effectByArm":[{"arm":"Placebo","deltaMin":92,"sd":null},{"arm":"Cariprazine","deltaMin":224,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0010"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":73,"countries":["United States","India","Romania","Slovakia","Ukraine"]},"refs":{"pmids":["34091867","33854317","30695290","27427558"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":765},"commonTop":["Akathisia","Insomnia","Headache","Restlessness","Extrapyramidal disorder"]}}